Lin Wei, the Chief Medical Officer of $RVMD, sold 2,073 shares of the company on 03-17-2026 for an estimated $206,222. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.0% of their shares of this class of stock. Following this trade, they now own 101,366 shares of this class of $RVMD stock.
$RVMD Insider Trading Activity
$RVMD insiders have traded $RVMD stock on the open market 45 times in the past 6 months. Of those trades, 0 have been purchases and 45 have been sales.
Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:
- MARK A GOLDSMITH (See Remarks) has made 0 purchases and 23 sales selling 220,265 shares for an estimated $16,635,256.
- MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 5 sales selling 84,430 shares for an estimated $8,370,274.
- JACK ANDERS (Chief Financial Officer) has made 0 purchases and 5 sales selling 31,275 shares for an estimated $2,534,090.
- JEFF CISLINI (General Counsel) has made 0 purchases and 7 sales selling 33,741 shares for an estimated $2,281,969.
- STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 3 sales selling 34,749 shares for an estimated $2,059,927.
- LIN WEI (Chief Medical Officer) sold 2,073 shares for an estimated $206,222
- XIAOLIN WANG (See Remarks) sold 2,010 shares for an estimated $199,955
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RVMD Hedge Fund Activity
We have seen 229 institutional investors add shares of $RVMD stock to their portfolio, and 171 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 3,482,061 shares (-72.8%) from their portfolio in Q4 2025, for an estimated $277,346,158
- WELLINGTON MANAGEMENT GROUP LLP removed 2,825,797 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $225,074,731
- AVORO CAPITAL ADVISORS LLC added 2,170,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $172,840,500
- JPMORGAN CHASE & CO removed 2,076,700 shares (-83.1%) from their portfolio in Q4 2025, for an estimated $165,409,155
- UBS GROUP AG added 1,998,972 shares (+183.6%) to their portfolio in Q4 2025, for an estimated $159,218,119
- A16Z CAPITAL MANAGEMENT, L.L.C. removed 1,827,424 shares (-66.5%) from their portfolio in Q4 2025, for an estimated $145,554,321
- GOLDMAN SACHS GROUP INC added 1,753,248 shares (+237.6%) to their portfolio in Q4 2025, for an estimated $139,646,203
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RVMD Analyst Ratings
Wall Street analysts have issued reports on $RVMD in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 01/20/2026
- Wolfe Research issued a "Outperform" rating on 11/18/2025
- Wedbush issued a "Outperform" rating on 11/06/2025
- Needham issued a "Buy" rating on 11/06/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/06/2025
- JP Morgan issued a "Overweight" rating on 11/06/2025
- RBC Capital issued a "Outperform" rating on 11/03/2025
To track analyst ratings and price targets for $RVMD, check out Quiver Quantitative's $RVMD forecast page.
$RVMD Price Targets
Multiple analysts have issued price targets for $RVMD recently. We have seen 14 analysts offer price targets for $RVMD in the last 6 months, with a median target of $140.0.
Here are some recent targets:
- Clara Dong from Jefferies set a target price of $140.0 on 03/16/2026
- Ami Fadia from Needham set a target price of $145.0 on 02/26/2026
- Eva Fortea Verdejo from Wells Fargo set a target price of $144.0 on 02/26/2026
- Kelsey Goodwin from Piper Sandler set a target price of $120.0 on 02/26/2026
- Brian Cheng from JP Morgan set a target price of $122.0 on 02/02/2026
- Jay Olson from Oppenheimer set a target price of $150.0 on 01/27/2026
- Laura Prendergast from Stifel set a target price of $170.0 on 01/22/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
